🟢 Alvotech is trading 6% up today following FDA acceptance of AVT80 for review

Alvotech is trading at ISK 634 (+5.67%), driven by the FDA’s acceptance of AVT80’s biologics license application for review on August 31, 2026.

• The review expands Alvotech’s proposed interchangeable Entyvio biosimilar into subcutaneous presentations.
• The treatment targets ulcerative colitis and Crohn’s disease, supporting optimism around Alvotech’s biosimilar pipeline.
• The announcement follows recent operational and liquidity updates but is the clearest company-specific catalyst.